Carlo Di Fonzo, vice president of drug development and regulatory affairs at Nektar Therapeutics, will be presenting on the preclinical and clinical development of NKTR-181, the company's investigational first-in-class, mu-opioid agnostic molecule, at Arrowhead's 10th Annual Pain & Migraine Therapeutics Summit on October 19, 2016 at 1:00 PM CDT.
Currently in Phase 3 clinical trials, NKTR-181 is a twice-daily oral tablet designed to provide relief to chronic pain sufferers without the abuse potential seen in existing opioids. Unlike other opioids, NKTR-181 is not a reformulation of a marketed opioid, but rather a reinvention of the opioid molecule itself, a design change that makes the actual drug less appealing to those who may crave the euphoric feeling associated with other opioids, but every bit as effective in managing pain.
In clinical studies, NKTR-181 has shown much less traditional opioid side effects such as sleepiness, dizziness and respiratory depression. Instead of euphoria, the patient will get only pain relief, thus removing the potential for addiction and - importantly - the fear many feel about taking opioid painkillers.
The 10th Annual Pain & Migraine Therapeutics Summit is the U.S.'s premier pain conference covering the field of pain research and therapeutics. With various stakeholders in pharmaceutical, biotech, device and medical communities attending, this conference will provide multi-faceted perspectives on the latest pain research. For more information on the 10th Annual Pain Summit, visit http://paintherapeuticsummit.com.
For more information, please contact:
John Waslif: Managing Director, Arrowhead Publishers
866-945-0263 ext 700
john.waslif@arrowheadpublishers.com
Rachel Donlon: Marketing Associate, Arrowhead Publishers
866-945-0263 ext 701
Rachel.donlon@arrowheadpublishers.com